Experience in Application of the Combinations Dorzolamide / Timolol and Brinzolamide / Timolol for the Prevention of Intraocular Hypertension in Patients with Silicone Oil Tamponade of the Vitreal Cavity

Purpose: to conduct a comparative analysis of the clinical efficacy of a fixed combination of antihypertensive drugs: brinzolamide 1 % = timolol 0.5 % and dorzolamide 2 % = timolol 0.5 % for the prevention of intraocular hypertension in patients with silicone oil tamponade of the vitreal cavity.

Patients and methods. The study was conducted in the Orenburg branch of S. Fyodorov Eye Microsurgery Federal State Institution during 2022. A retrospective analysis of case histories of 60 patients with retinal detachment and severe proliferative syndrome was carried out. All patients underwent subtotal vitrectomy. To prevent intraocular hypertension after tamponade of the vitreal cavity with silicone oil, patients were prescribed antihypertensive drugs: group 1 (n = 30) — a combination of brinzolamide 1 % = timolol 0.5 %; group 2 (n = 30) — dorzolamide 2 % = timolol 0.5 %. The therapeutic result was evaluated after 2 weeks, 1, 2 and 3 months. The observation included an ophthalmological examination, as well as a questionnaire to assess drug tolerance.

Results. IOP after silicone oil tamponade and before the application of drugs had no statistically significant differences between the studied groups and amounted to 27.15 ± 3.56 mm Hg — in group 1 and 28.53 ± 5.99 mm Hg — in group 2. Both studied combinations provided a decrease in IOP, however, a more pronounced effect after 2 weeks of therapy with subsequent maintenance of a normal IOP level for 3 months was recorded in group 2 when using the dorzolamide / timolol combination, despite the appearance of minor discomfort during instillation. A decrease in IOP from baseline was found to be 43.5 % (p ≤ 0.01) with the combination dorzolamide/timolol and 33.3 % (p ≤ 0.01) for brinzolamide/timolol.

Conclusion. The results of the study showed that both fixed combinations of drugs provide a decrease in IOP in patients after silicone tamponade, but the dorzolamide/timolol combination had a more pronounced therapeutic effect.

1. Chen Y, Kearns VR, Zhou L, Sandinha T, Lam WC, Steel DH, Chan YK. Silicone oil in vitreoretinal surgery: indications, complications, new developments and alternative longterm tamponade agents. Acta Ophthalmol. 2021;99(3):240–250. doi: 10.1111/aos.14604.

2. Barca F, Caporossi T, Rizzo S. Silicone oil: different physical proprieties and clinical applications. Biomed Res Int. 2014;2014:502143. doi: 10.1155/2014/502143.

3. Morescalchi F, Costagliola C, Duse S, Gambicorti E, Parolini B, Arcidiacono B, Romano MR, Semeraro F. Heavy silicone oil and intraocular inflammation. Biomed Res Int. 2014;2014:574825. doi: 10.1155/2014/574825.

4. Coman (Cernat) CC, Munteanu M, Patoni (Popescu) SI, Musat O. Silicone oil complications in vitreoretinal surgery. Rom J Ophthalmol. 2022;66(4):299–303. doi: 10.22336/rjo.2022.55.

5. Schaub F, Enders P, Fauser S. Proliferative Vitreoretinopathy: Therapeutic Strategies. Klein Monbl Augenheilkd. 2016;233(9):1016–1023. doi: 10.1055/s‑0042‑107947.

6. Hocaoglu M, Karacorlu M, Ersoz MG, Muslubas IS, Arf S. Vitrectomy with silicone oil tamponade for retinal detachment associated with giant retinal tears: Favourable outcomes without adjuvant scleral buckling. Acta Ophthalmol. 2019;97(2):e271– e276. doi: 10.1111/aos.13895.

7. Vidne‑Hay O, Platner E, Alhalel A, Moisseiev J. Long‑term silicone oil tamponade in eyes with complicated retinal detachment. Eur J Ophthalmol. 2022;32(3):1728– 1734. doi: 10.1177/11206721211019551.

8. Sonmez K, Hekimsoy HK. Outcomes and predictors of vitrectomy and silicone oil tamponade in retinal detachments complicated by proliferative vitreoretinopathy. Int J Ophthalmol. 2022;15(8):1279–1289. doi: 10.18240/ijo.2022.08.09.

9. Nicolai M, Lassandro N, Franceschi A, Rosati A, De Turris S, Pelliccioni P, Pirani V, Mariotti C. Intraocular Pressure Rise Linked to Silicone Oil in Retinal Surgery: A Review. Vision (Basel). 2020;4(3):36. doi: 10.3390/vision4030036.

10. Fang Y, Long Q, Wang X, Jiang R, Sun X. Intraocular pressure 1 year after vitrectomy in eyes without a history of glaucoma or ocular hypertension. Clin Ophthalmol. 2017;11:2091–2097. doi: 10.2147/OPTH.S144985.

11. Valentín‑Bravo FJ, García‑Onrubia L, Andrés‑Iglesias C, Valentín‑Bravo E, MartínVallejo J, Pastor JC, Usategui‑Martín R, Pastor‑Idoate S. Complications associated with the use of silicone oil in vitreoretinal surgery: A systemic review and metaanalysis. Acta Ophthalmol. 2022;100(4):e864–e880. doi: 10.1111/aos.15055.

12. Jabbour E, Azar G, Antoun J, Kourie HR, Abdelmassih Y, Jalkh A. Incidence and Risk Factors of Ocular Hypertension following Pars Plana Vitrectomy and Silicone Oil Injection. Ophthalmologica. 2018;240(3):129–134. doi: 10.1159/000489792.

13. Konstas AG, Schmetterer L, Katsanos A, Hutnik CML, Holló G, Quaranta L, Teus MA, Uusitalo H, Pfeiffer N, Katz LJ. Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future. Adv Ther. 2021;38(1):24– 51. doi: 10.1007/s12325‑020‑01525‑5.

14. Petrov SYu, Volzhanin AV. A review of the clinical experience of the therapy of glaucoma and ophthalmic hypertension with a fixed combination of dorzolamide and timolol. Russian Medical Journal. Clinical Ophthalmology. 2017;2:100–106 (In Russ.). doi: 10.21689/2311‑7729‑2017‑17‑2‑100‑106.

15. Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure‑lowering effects of commonly used fixed‑combination drugs with timolol: a systematic review and meta‑analysis. PloS One. 2012;7(9):e45079. doi: 10.1371/journal.pone.0045079.

16. Sanseau A, Sampaolesi J, Jr ERS, Lopes JF, Borel H. Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open‑angle glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:357–362. doi: 10.2147/OPTH.S38575.

17. Akсay BIS, Güney E, Bozkurt KT, Unlü C, Akcali G. The safety and efficacy of brinzolamide 1 % / timolol 0.5 % fixed combination versus dorzolamide 2 % / timolol 0.5 % in patients with open‑angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2013;29(10):882–886. doi: 10.1089/jop.2013.0102.

18. Galose MS, Elsaied HM, Macky TA, Fouad PH. Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital‑based, prospective, randomized study. Indian J Ophthalmol. 2016;64(2):127–131. doi: 10.4103/0301‑4738.179718.

19. Meier‑Gibbons F, Töteberg‑Harms M. Structure/function/treatment in glaucoma: progress over the last 10 years. Ophthalmologe. 2021;118(12):1216–1221. doi: 10.1007/s00347‑021‑01505‑2.

20. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. doi: 10.1001/archopht.120.10.1268.

21. Russo A, Morescalchi F, Donati S, Gambicorti E, Azzolini C, Costagliola C, Semeraro F. Heavy and standard silicone oil: intraocular inflammation. Int Ophthalmol. 2018;38(2):855–867. doi: 10.1007/s10792‑017‑0489‑3.

22. Semeraro F, Russo A, Morescalchi F, Gambicorti E, Vezzoli S, Parmeggiani F, Romano MR, Costagliola S. Comparative assessment of intraocular inflammation following standard or heavy silicone oil tamponade: a prospective study. Acta Ophthalmol. 2019;97(1):e97–e102. doi: 10.1111/aos.13830.

23. Liu Z, Fu G, Liu A. The relationship between inflammatory mediator expression in the aqueous humor and secondary glaucoma incidence after silicone oil tamponade. Exp Ther Med. 2017;14(6):5833–5836. doi: 10.3892/etm.2017.5269.

24. Al‑Jazzaf AM, Netland PA, Charles S. Incidence and management of elevated intraocular pressure after silicone oil injection. J Glaucoma. 2005;14(1):40–46. doi: 10.1097/01.ijg.0000145811.62095.fa.

25. Kchlobystov AA, Egorov EA, Stavitczkaya TV. Brinzolamide — new carboanhidrase inhibitor. Russian Medical Journal. Clinical Ophthalmology 2001;2:51–54 (In Russ.).

26. Stoner A, Harris A, Oddone F, Belamkar A, Vercellin ACV, Shin J, Januleviciene I, Siesky B. Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand? Br J Ophthalmol. 2022;106(10):1332–1337. doi: 10.1136/bjophthalmol‑2021‑319530.

27. Moshetova LK, Soshina MM, Sychev DA, Turkina KI. Pharmacogenetics of timolol. Annales of Ophthalmology. 2019;135(3):137–143 (In Russ.). doi: 10.17116/oftalma2019135031137.

28. Nebbioso M, Evangelista M, Librando A, Di Blasio D, Pescosolido N. Fixed topical combinations in glaucomatous patients and ocular discomfort. Expert Opin Pharmacother. 2012;13:1829–1835. doi: 10.1517/14656566.2012.705830.

29. Altafini R, Scherzer ML, Hubatsch DA, Frezzotti P. Brinzolamide 1 %/timolol versus dorzolamide 2 %/timolol in the treatment of open‑angle glaucoma or ocular hypertension: prospective randomized patient‑preference study. Clin Ophthalmol. 2015;9:2263–2270. doi: 10.2147/OPTH.S88891.

30. Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Comparative effectiveness of first‑line medications for primary open‑angle glaucoma: a systematic review and network meta‑analysis. Ophthalmology. 2016;123:129–140. doi: 10.1016/j.ophtha.2015.09.005.